-
Posted by
Two Blokes Tue at 10:30 AM -
Filed in
Stock
-
2 views
Novo Nordisk has a strong economic moat based on significant market shares in diabetes and obesity care, and promising pipeline drugs, though facing competition and political pressures. The company shows very high profitability and about 20% EPS and dividend growth. My Fair Value estimate, derived from three distinct sources, is $83, suggesting about 27% potential upside.
